期刊
CLINICAL & EXPERIMENTAL METASTASIS
卷 39, 期 1, 页码 201-211出版社
SPRINGER
DOI: 10.1007/s10585-021-10100-3
关键词
Melanoma; Metastatic melanoma; In transit melanoma; Regional perfusion chemotherapy; Isolated limb infusion; T-VEC
类别
Management of in-transit melanoma involves a variety of treatment pathways based on disease characteristics and patient preferences. While surgical excision, regional perfusion, and systemic therapies are common options, some therapies can effectively treat unresectable disease. The use of systemic therapies for in-transit melanoma lacks specific data but is explored in clinical trials for synergistic benefits with other therapies.
Management of in-transit melanoma encompasses a variety of possible treatment pathways and modalities. Depending on the location of disease, number of lesions, burden of disease and patient preference and characteristics, some treatments may be more beneficial than others. After full body radiographic staging is performed to rule out metastatic disease, curative therapy may be performed through surgical excision, intraarterial regional perfusion and infusion therapies, intralesional injections, systemic therapies or various combinations of any of these. While wide excision is limited in indication to superficial lesions that are few in number, the other listed therapies may be effective in treating unresectable disease. Where intraarterial perfusion based therapies have been shown to successfully treat extremity disease, injectable therapies can be used in lesions of the head and neck. Although systemic therapies for in-transit melanoma have limited specific data to support their primary use for in-transit disease, there are patients who may not be eligible for any of the other options, and current clinical trials are exploring the use of concurrent and sequential use of regional and systemic therapies with early results suggesting a synergistic benefit for oncologic response and outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据